Iterum Therapeutics plc (ITRMF) Net Income towards Common Stockholders (2017 - 2025)

Iterum Therapeutics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$9.0 million in Q3 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 47.34% year-over-year to -$9.0 million in Q3 2025; TTM through Sep 2025 was -$27.0 million, a 11.76% increase from a year earlier, with the FY2024 full-year figure at -$24.8 million, up 35.44% from the prior year.
• Net Income towards Common Stockholders was -$9.0 million for Q3 2025 at Iterum Therapeutics, down from -$6.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $7.8 million in Q2 2021, with the low at -$98.9 million in Q1 2021.
• Average Net Income towards Common Stockholders over 5 years is -$11.6 million, with a median of -$6.5 million recorded in 2025.
• The sharpest annual moves came in 2021 and 2022: Net Income towards Common Stockholders soared 162.28% in 2021, then tumbled 878.11% in 2022.
• Over 5 years, Net Income towards Common Stockholders stood at -$4.2 million in 2021, then dropped by 21.71% to -$5.1 million in 2022, then plunged by 142.87% to -$12.4 million in 2023, then soared by 46.76% to -$6.6 million in 2024, then tumbled by 36.42% to -$9.0 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$9.0 million (Q3 2025), -$6.5 million (Q2 2025), and -$4.9 million (Q1 2025), per Business Quant data.